^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
Published date:
07/07/2023
Excerpt:
CONTRADICTING EVIDENCE: The purpose of the current retrospective analysis was to evaluate whether the mutational signature of metastatic melanoma had an impact on ICI treatment outcomes such as progression-free and overall survival....The percentage of patients who achieved CR as the BORR after initial ICI treatment was 45.5% for the BRAF V600 mutation subset, 38.5% for NRAS mutant patients, 37.5% for NF1 mutant patients, and 55.6% for triple negative patients (p > 0.05 via chi-square test). No patients with a BRAF fusion or gene rearrangement responded to ICI or 2nd line PD-1 antibody plus targeted therapy treatment (BORR of 0%)....
DOI:
https://doi.org/10.3390/cancers15133527
Source:
Title:
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
Published date:
01/11/2022
Excerpt:
We identified 27 SMGs, including four novel SMGs (COL3A1, NRAS, NARS2, and DCC) that are associated with ICI efficacy and well-known driver genes. COL3A1 mutations were associated with improved ICI overall survival (hazard ratio (HR): 0.64, 95% CI: 0.45–0.91, p = 0.012), whereas immune resistance was observed in patients with NRAS mutations (HR: 1.42, 95% CI: 1.10–1.82, p = 0.006).
DOI:
10.3389/fimmu.2021.798474
Source:
Title:
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
Published date:
12/15/2020
Excerpt:
Next-generation sequencing (NGS) was performed using tumor specimens collected from 178 Asian patients with metastatic melanoma receiving CPIs….NRAS mutations, TP53 mutations, and NF2 deletions were significantly associated with resistance to CPIs (P < 0.05).
DOI:
10.1016/j.esmoop.2020.100002
Source:
Title:
Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.
Published date:
05/13/2020
Excerpt:
NRAS and TP53 mutation and NF2 deletion were significantly related to patients without the response to CPIs (p < 0.05). Meanwhile, MYC and RPS6KB1 amplification were found with those with the response (p < 0.05). The median progression free survival (PFS) to ICIS was 5.9 months (95% CI 3.8 - 8.05 months).
DOI:
10.1200/JCO.2020.38.15_suppl.e22011
